Wednesday, 21 February 2018 - 4:07
  • it
  • de
  • en
  • fr

Top stories

News of the week

Vasant Narasimhan, Novartis CEO, describes group’s R&D strategy

41-year-old Novartis new CEO Vasant Narasimhan has announced his R&D strategy for the Basel-based group. Narasimhan is seeking to innovate the data science and digital technologies divisions, which he expects to be the development drivers for new drugs. Additionally, the…

Approvals

Procedures / New drug and device authorizations / Recommendations

New FDA approval for AstraZeneca’s Imfinzi

FDA has approved the cancer drug Imfinzi for the treatment of stage III lung cancer on patients who have already been treated with chemotherapy and radiation therapy. The approval reflects the positive data from the Pacific clinical trial. Analysts believe…

Companies

Healthcare market news

Vasant Narasimhan, Novartis CEO, describes group’s R&D strategy

41-year-old Novartis new CEO Vasant Narasimhan has announced his R&D strategy for the Basel-based group. Narasimhan is seeking to innovate the data science and digital technologies divisions, which he expects to be the development drivers for new drugs. Additionally, the…

Chemistry

Market and Technology

Saudi Aramco partners with Russia-based Sibur

Russian website Prime has reported that Russia-based chemical group Sibur and Saudi Arabia-based Saudi Aramco have entered into a partnership. As part of the agreement, a new elastomers and rubber production facility will be built in Saudi Arabia. The companies…

2D materials fit for business?

Sabic purchases 25% in Clariant

M&A

Mergers & Acquisitions

Crispr Therapeutics: the Swiss biotech raising everyone’s expectations

The recent success of CRISPR technology has brought benefit to the Switzerland-based biotech Crispr Therapeutics, which is attracting attention from investors and competitors. The company’s shares have risen over 70% since the start of the year, and 121% over the…

Nutraceuticals

Food supplements

Research on brain-bacterial flora links, state of the art: first results on sleep and memory

The scientific journal Science Immunology (AAAS) has published today two important articles concerning the latest findings about the function of intestinal bacterial flora. The first studies date back to the 90s, when researchers first understood that intestinal bacteria play a…

Pathology

Latest developments

Research on brain-bacterial flora links, state of the art: first results on sleep and memory

The scientific journal Science Immunology (AAAS) has published today two important articles concerning the latest findings about the function of intestinal bacterial flora. The first studies date back to the 90s, when researchers first understood that intestinal bacteria play a…

Safety

News on Product Safety

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Research on brain-bacterial flora links, state of the art: first results on sleep and memory

The scientific journal Science Immunology (AAAS) has published today two important articles concerning the latest findings about the function of intestinal bacterial flora. The first studies date back to the 90s, when researchers first understood that intestinal bacteria play a…